8:00 am Registration & Breakfast

8:50 am Chair’s Opening Remarks

Widening the Therapeutic Window With a Varied Approach to Cell Engagement That Involves the Entire Immune System

9:00 am A Multipronged Approach to Activating the Power of the Innate Immune System: Innate Cell Engagers Monotherapy or in Combination with Other Agents

  • Joachim Koch Senior Director, Head Translational Research & Innovation, Affimed GmbH


  • Demonstrating the growing body of evidence that innate cell engagement provides new therapeutic options for patients in need
  • Sharing new data of Affimed’s Innate Cell Engagers (ICE® molecules) AFM13, AFM24 and AFM28
  • Outlining the three-pronged approach with the ICE® as monotherapy, or in combination with NK cell products or checkpoint inhibitors

9:30 am Panel Discussion: Leveraging Innate & Adaptive Systems to Open the Therapeutic Window with Novel, Rational Combinations

  • John Rossi Senior Vice President, Head of Translational Medicine , Cero Therapeutics Inc.
  • Sebastian Nijman Founder & Chief Scientific Officer Scenic, Biotech BV


  • Which approach holds more potential: doubling down on T-Cell activity through combination therapy with PD-1/PD-L1 (for example), or harnessing alternative cell types such as innate immune cell engagers and gamma delta T-Cells?
  • Evaluate the key risks and opportunities presented by each of these approaches
  • Consider the limitations of these areas
  • Discuss the ideal sequencing of agents to form a sustained response
  • What are the key risks and opportunities that are presented by each of these approaches?
  • What are the limitations of these areas?
  • What is the ideal sequencing of agents to induce a sustained response?

10:00 am Mechanistic Modeling to Optimize Doses For Receptor Crosslinking & Checkpoint Blockade: a Case Study With a 41BB/ PDL1 Bispecific Antibody

  • Alison Betts Vice President of Scientific Collaborations & Fellow of Modeling & Simulation, Applied Biomath


  • ATG-101 is a bispecific antibody that crosslinks tumor-expressed PD-L1 to T-cell expressed 4-1BB, thereby selectively activating T-cells infiltrating solid tumors while inhibiting immune checkpoints
  • To activate 41BB, the molecule requires to crosslink tumor cells and T cells to form trimeric complexes (“trimers’), which have a bell-shaped relationship with dose. To block PDL1, the molecule must achieve sufficient target coverage (>90%). These opposing pharmacologies can complicate dose selection
  • Learn how a mechanistic model was developed, calibrated and benchmarked to preclinical in vitro and in vivo data, and used to predict both optimal trimer formation and PDL1 receptor occupancy to guide rational clinical dose selection

10:30 am
Morning Refreshments

Combatting Cytokine Release Syndrome & Other Toxicities

11:15 am Tritac-XR: An Extended-Release T Cell Engager Platform Designed to Minimize Cytokine Release Syndrome

  • Rick Austin Vice-President Research, Harpoon Therapeutics


  • Explore how T cell engagers are potent drugs, but their development can be hindered by cytokine release syndrome (CRS)
  • Understand how TriTAC-XR molecules are engineered T cell engager prodrugs that become slowly activated by proteases in circulation
  • Assess how TriTAC-XR’s extended-release mechanism reduces cytokine levels in cynomolgus monkey while generating pharmacodynamic effects comparable to a constitutively active T cell engager

Harnessing Co-Stimulatory Targets to Enhance Therapeutic Binding

11:45 am Engineered Cytokines Targeting Immune Effectors & Regulatory Cells


Explore the potential of the following:

  • Engineered IL-15 to drive immune effectors in cancer therapy
  • Engineered low potency IL-12 to improve therapeutic index in cancer
  • Engineered IL-2 to drive Tregs to treat autoimmunity

12:15 pm Drugs & Trials in the Cell Engager Space

  • Shailee Patel Research Analyst, Beacon Bispecific – Beacon Targeted Therapies


  • Current Landscape
  • Drugs Entered into the Clinic
  • Top Targets
  • Developers

Inducing a Safer & More Sustained Immune Gamma Delta Response by Targeting Innate Immune Cell Engagers & γδ T-Cells

12:45 pm Gamma-Delta T-Cells: Novel Approaches to Genetic Engineering & Cell-Type Specific Therapeutic Applications

1:15 pm
Lunch Break

2:15 pm Targeting Tumor Macrophages to Change the Tumor Microenvironment from Immunosuppressive to Immune Active


  • Identifying synergy with checkpoint inhibitors, radiation and chemotherapy
  • Review current progress in the field

2:45 pm QPCTL: A Small Molecule Drug Target Modulating the Innate Immune Response


  • Hear how Scenic is developing a small molecule therapeutic in the oncology space
  • Understand how QPCTL modulates 2 key innate immune pathways, including CD47/SIRPa
  • Explore how QPCTL is a well understood MoA and extensively validated

3:15 pm Cancer Immunotherapy Using TGF-Beta Conditioned Gamma Delta T Cells

  • John Maher Chief Scientific Officer , Leucid Bio


  • Explore how TGF-Beta enhances the yield and viability of expanded gamma delta T-cells
  • Discuss how gamma delta cells achieve more efficient tumor cell killing and cytokine release and resist suppression by TGF-Beta or PGE2
  • Understand how gamma delta cells mediate enhanced anti-tumor and anti-leukemic activity

3:45 pm Chair’s Closing Remarks

3:50 pm End of Conference